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Abstract 
Epidemiology and experimental models have shown a close link between adipose tissue inflammation, systemic 
inflammation and pulmonary neutrophilic inflammation, which predispose obese patients to pulmonary 
diseases, obesity-associated co-morbidities and cancer. Increased content and activation of neutrophils in the 
lung microvasculature, resulting from peripheral activation of neutrophils, and increased adhesion of 
neutrophils to the lung microvasculature are important factors explaining the increased susceptibility of obese 
patients towards respiratory diseases and loss of insulin sensitivity. Mechanism-based therapies to break this 
link are urgently needed to reduce pulmonary damage in obesity, due to the growing prevalence of obesity 
world-wide. Current research suggests that these approaches should be focused on, one or more of the 
following: reduction of macrophage activation at the adipose tissue, healthy growing of adipose tissue by 
induction of Nrf-2, inhibition of NF-B activation, reduction of circulating neutrophil activation, blocking 
adhesins/selectins, inhibition of neutrophil activation by targeting NADPH oxidase-2 activation, inhibition of 
myeloperoxidase activity and scavenging of hypochlorous acid. These strategies are expected to reduce adipose 
tissue inflammation, peripheral inflammation, pulmonary neutrophilic inflammation and obesity-associated co-
morbidities.  
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Adipose Tissue and Systemic 
Inflammation in Obesity 
 
Obesity is a frequent, costly and serious chronic 
inflammatory disease. This disease is 
characterized by a state of low-grade chronic 
inflammation resulting of a chronic positive 
energy-balance [1,2]. When adipose tissue 
capacity to store energy is overwhelmed, excess 
free fatty acids (FFAs) increase in circulation [3] 
where it can activate a number of vasculatures and 
circulating innate immune cells, such as 
monocytes and neutrophils [4,5]. Increased 
circulating activated neutrophils have been 
observed in obese patients [6]. This activation 
process may be caused by inflammatory factors 
such as end-oxidation products of 
macromolecules, as well as pro-inflammatory 
cytokines released by the inflamed adipose tissue 
[7,8]. Intestinal microbiota is also a factor to 
consider due to the increased intestinal 
permeability to endotoxin that can translocate into 
the systemic circulation and activate peripheral 
cells, as well as distant tissue vasculatures [1-9].  
 
Adipose tissue inflammation is a multifactorial 
process that involves a number of causes, 
including adipose extracellular matrix stress, 
endotoxin translocation from the gut into 
circulation, macrophage infiltration, hypoxia, 
endoplasmic reticulum-stress and mitochondrial 
dysfunction [2,7,10,12]. Products released by the 
inflamed adipose tissue reach systemic 
circulation, where they can activate leukocytes 
and other tissue cells.   
 
Adipose tissue macrophages derive from 
circulating monocytes. Under normal conditions 
these monocytes are differentiated into 
macrophages with an M2 anti-inflammatory 
phenotype; and their function is the patrol of the 
tissue for damaged/death cells, tissue reparation 
and remodeling [10]. However, under metabolic 
stress conditions caused by hypoxia, endoplasmic 
reticulum (ER)-stress and FFAs, monocytes are 
recruited in large numbers and differentiated into 
pro-inflammatory M1-macrophages [10,13]. The 
pro-inflammatory phenotype of these 
macrophages is caused mainly by activation of the 
nuclear factor-B (NF-B) signaling pathway 
[14]. This activation leads to expression of a 
number of pro-inflammatory 
cytokines/chemokines and large production of 
reactive biochemical species. Adipocyte 
hypertrophy and monocyte infiltration are the 
most relevant events in adipose tissue 
inflammation, because they are associated with 
the phenotypic switch of macrophage towards 
M1-proinflammatory cells located at hypoxic 
areas within the adipose tissue, crown-like 
structures [11,13,15].  
 
Deregulated secretion of inflammatory mediators 
by a growing mass of fat tissue in obesity is a risk 
factor for biochemical stress in the lung of obese 
patients [16]. Figure 1 shows some of the 
pulmonary complications observed in obese 
patients and in animal models of obesity. These 
complications are the result of mechanical and 
biochemical pressures in obese patients and 
animals. Adipokines are proteins that are mainly 
or exclusively produced by adipocytes, and 
responsible for many of the pulmonary 
complications in obesity [17]. Examples include 
leptin, resistin and adiponectin, which have 
potential immunomodulatory effects in 
pulmonary cells [17,18]. Genetically obese 
ob/ob mice, which produce a mutated, non-
functional form of leptin, show many of the 
same inflammatory changes as other models of 
obesity (including diet-induced obese mice), and 
ob/ob mice become both insulin resistant and 
diabetic [19]. These results indicate that leptin 
may not have a particularly important role in 
obesity-induced inflammation [20]. Adiponectin 
is considered to be an anti-inflammatory, 
insulin-sensitizing and cardioprotective 
protein [17,21-23]. It may cause these effects 
in several pathways; for example, by inducing 
anti-inflammatory cytokines such as IL-10 and 
IL-1Ra, through vascular mechanisms includ-
ing enhancement of nitric oxide bioavailability, or 
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Figure 1: Pulmonary complications of obesity. Image shows a number of pulmonary complications 
observed in obese patients caused by adipose tissue-derived systemic inflammation. COPD, chronic-
obstructive pulmonary disease. 
 
In obesity, a low-grade chronic state of 
inflammation is responsible for multiple organs 
dysfunction [10]. Systemic inflammation 
produced by the inflamed fat has been 
correlated with the development of insulin 
resistance, a hallmark of type 2 diabetes 
mellitus (T2DM) as well as a number of chronic 
inflammatory diseases and cancer [2,26].  
 
The Lung Microvasculature Homes 
More Neutrophils in Obesity  
 
Inflammation mediators (pro-inflammatory 
cytokines/chemokines and macromolecule end-
oxidation products) released by the adipose 
tissue [11] may activate both, circulating 
neutrophils and peripheral microvasculatures 
(Figure 2). Therapies aimed at reducing 
activation of neutrophils, recruitment of 
neutrophils into tissues and adhesion molecules 
in microvasculature may have clinical benefit in 
the future to overcome tissue damage induced 
by excessive leukocyte infiltration [6,27]. In 
addition, obese and leptin-supplemented mice 
are more sensitive to ozone-induced lung 
inflammation than their lean counterparts [28]. 
This evidence suggests that in obese patient’s 
leptin and/or resistin may cause lung 
inflammation by increasing neutrophil content, 
and possibly their activation, in the lung 
microvasculature [29-31]. In pathological 
conditions such as asthma and chronic 
obstructive pulmonary disease (COPD), it is 
likely that the tracheal-bronchial circulations 
are pivotal in the recruitment of circulating 
leukocytes [29,32]. Furthermore, the 
mechanism of the airway circulation for the 
recruitment of inflammatory cells in obesity 
after the inhalation of airborne pollutants 
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Adipose tissue inflammation in obesity 
produces a number of inflammation 
mediators. These cause activation of 
neutrophils in circulation and endothelial cells 
in the lung. This process results in increased 
content and activation of neutrophils and 
MPO-promoted oxidation reactions and 
pulmonary inflammation. Under this 
condition the lung acts as an extra source of 
inflammation mediators that contribute 
towards systemic inflammation and worsen 
obesity-associated co-morbidities and cancer.  
AGE, advanced-glycation end-products; 
ALE, Advanced-lipid peroxidation end-
products; APE, Advanced-protein oxidation-
end products.  
 
Neutrophils are key sentinel cells of the innate 
immune system and are the premier cellular 
responders to acute inflammation [33,34]. For 
example, in models of acute lung injury ranging 
from acid aspiration to ischemia- reperfusion, 
depletion of neutrophils before the injury 
stimulus protects rabbits, rats and mice, 
respectively, from lung injury. These 
noninfectious models differ from the most 
common clinical causes of acute lung injury, 
pneumonia and sepsis, in which neutrophils are 
needed to control the infection. Nonetheless, 
animal work has demonstrated that the pro-
inflammatory response of the neutrophil can lead 
to an increase in endothelial and epithelial 
permeability and, in the case of sepsis, shock 
and global organ injury [35,36]. 
  
The lung microcirculation has a concentration 
and traffic of neutrophils 30-100-times higher 
than any other large vasculatures in the human 
body, which might be further increased during 
obesity, making it a potential source of 
oxidants, oxidized products and pro-
inflammatory cytokines upon exposure to air 
pollutants [37-40]. Airway inflammation 
requires an orchestrated series of molecular 
events whereby inflammatory cells leave the 
airway vasculature and migrate within the 
airway space [41]. Leukocytes are initially 
tethered to the endothelial cell surface of post-
capillary venules, then roll, before firmly 
adhering and subsequently migrating out of the 
vasculature [42]. In obesity, circulating 
inflammation mediators derived from an 
inflamed adipose tissue, have been shown to 
produce oxidative stress in the brain and muscle 
tissue, both cardiac and skeletal, but the 
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information in lung is limited [43]. Among the 
pro-inflammatory adipokines secreted in high 
quantities by the inflamed fat tissue, leptin, 
TNF-, MCP-1, IL-1 and resistin have been 
shown to increase intercellular-adhesion 
molecule-1 (ICAM-1) expression in endothelial 
cells and to slow neutrophil rolling [16]. These 
adipokines and other inflammatory mediators 
in the serum of obese patients are thought to be 
a leading cause of systemic inflammation and 
thus obesity-associated metabolic disorders 
[37,40].  
 
Leukocyte-endothelial cell interactions are 
mediated by various cell adhesion molecules 
[44]. These interactions are important for 
leukocyte extravasation and trafficking in all 
domestic animal species. An initial slowing of 
leukocytes on the vascular endothelium is 
mediated by selectins [45]. This event is 
followed by activation of 2-integrins after 
leukocyte exposure to cytokines and pro-
inflammatory mediators, adherence of 
leukocyte 2 integrins to vascular endothelial 
ligands (e.g., ICAM-1), extravasation of 
leukocytes into tissues through tight junctions 
of endothelial cells mediated by platelet and 
endothelial cell adhesion molecule-1 (PECAM-
1), and perivascular migration through the 
extracellular matrix via 1 integrins [42,46]. 
Inhibiting excessive leukocyte egress and 
subsequent free radical-mediated damage 
caused by leukocyte activation may attenuate or 
eliminate tissue damage [47]. Several methods 
have been used to modify leukocyte infiltration 
in various animal models [48]. These methods 
include nonspecific inhibition of pro-
inflammatory mediators and adhesion 
molecules by nonsteroidal anti-inflammatory 
drugs and glucocorticoids, inhibition of 
cytokines and cytokine receptors, and 
inhibition of specific types of cell adhesion 
molecules, with inhibitors such as peptides and 
antibodies to 2 integrins, and inhibitors of 
selectins, ICAMs, and vascular cell adhesion 
molecule-1 (VCAM-1) [46]. By understanding 
the cellular and molecular events in leukocyte-
endothelial cell interactions, therapeutic 
strategies are being developed in several animal 
models and diseases in which neutrophilic 
inflammation plays a role. 
 
Oxidations Promoted by Pulmonary 
Neutrophilic Inflammation and Systemic 
Inflammation in Obesity 
 
Previously an increased activation of 
neutrophils in the systemic inflammation 
induced by adipose tissue inflammation has 
been reported [49]. We have also shown 
increased of neutrophil accumulation and 
activation in the lung of diet-induced obesity 
mouse model [50]. Neutrophil activation was 
associated with more oxidative stress and 
inflammation in the lung and systemic 
environments [17,51,52]. This effect caused 
reduced insulin sensitivity that was improved 
by decreasing neutrophil homing, 
myeloperoxidase activation or by scavengers of 
HOCl (unpublished data). The main players in 
causing lung inflammation induced by 
environmental and metabolic stressors are 
neutrophils and myeloperoxidase (MPO), an 
enzyme contained in neutrophils’ azurophilic 
granules [51,53]. MPO is the only mammalian 
enzyme that, under physiological conditions, 
produces HOCl [54]. MPO can produce a 
number of hypohalous (e.g., HOCl, IOH and 
BrOH) and pseudo-hypohalous (e.g., SCNOH) 
compounds [55]. MPO uses H2O2 to oxidize 
chloride anions into hypochlorous 
acid/hypochlorite (HOCl/−OCl, from now on 
HOCl), a potent oxidizing agent [56]. 
Hypochlorous acid further reacts with other 
biological molecules to generate secondary 
reactive species, such as chloramines and 
NO2Cl [56,57]. Determination of blood MPO 
and HOCl-modified proteins have been 
suggested a predictive biomarker of 
cardiovascular accident [52].  
 
Activation of neutrophils and production of 
HOCl in the lung vasculature causes oxidative 
stress and inflammation in the lung [50,52]. On 
the other hand, inhalation of air pollutants is 
associated with altered serum biomarkers of 
oxidative stress and inflammation (BOSI) and a 
higher incidence of insulin resistance in swine 
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farm workers [58]. The incidence of 
cardiovascular diseases has been reported to 
increase in humans driving cloudy routes 
during rush hours [59,60]. The prevalence of 
airway sensitization in obese is higher than lean 
subjects [51,61] (See Figure 1). This evidence 
has been also supported in obese experimental 
animals [32]. Therefore, it is possible that 
inhalation of air pollutants increases the 
incidence of systemic inflammation and 
obesity-associated metabolic complications in 
obese patients (BMI>30 Kg/m2) in relation to 
normal weight subjects [2]. This disparity 
between obese and lean patients to develop 
obesity-associated diseases upon inhalation of 
air pollutants can be prevented by blocking free 
radical processes in the obese lung with specific 
antioxidants that target MPO or MPO-derived 
oxidants, such as HOCl (Figure 2). Using 
genetically modified mice which are unable to 
release superoxide anions and superoxide-
derived oxidants from NAD(P)H oxidases 
(NOX), it has been found that PM2.5 increases 
obesity and insulin resistance in vivo by 
NAD(P)H oxidase-derived superoxide anions 
[62]. Superoxide anions and their derived oxidants 
including hydrogen peroxide and peroxynitrite 
are known to suppress vascular endothelial 
function and lower insulin responsiveness [62]. 
The NAD(P)H oxidase, a membrane-bound 
enzyme complex, consists of multiple subunits 
including p22phox, p40phox, p47phox, p67phox, NoxO1, 
NoxA1, Rac1, and gp91phox-related unique isoforms 
of Nox [63]. The complex is normally latent in 
neutrophils and is activated to assemble in the 
membranes during respiratory burst [64]. The 
choice of Xu et. al. to target the p47phox subunit 
of NAD(P)H was based on its homology in both 
phagocytic and nonphagocytic inflammatory 
pathways that are implicated in NAD(P)H-
mediated insulin resistance [65]. In an elegant 
series of experiments using C57BL6 and p47phox 
homozygous knockout mice, the investigators 
have systematically assembled evidence that 
PM2.5 exposure when the animals were 3-
week-old young pups, induced a later life 
phenotype that manifested increase in 
abdominal fat, increased adipocyte size, and 
heightened inflammatory cellular response 
[65]. This study suggests that early life exposure 
to PM2.5 scale particulate pollution primes the 
system toward developing insulin resistance and 
a proinflammatory vascular phenotype in later 
life, likely via NAD(P)H oxidase–derived 
superoxide anions. 
 
Therapeutic Targets  
 
The link between adipose tissue inflammation, 
systemic inflammation and pulmonary 
neutrophilic inflammation should be interesting 
to break because pulmonary inflammation can 
contribute to the systemic pool of inflammation 
mediators that can worsen systemic 
inflammation, and consequently obesity-
associated co-morbidities, such as insulin 
resistance (Figure 2). Obviously, the most 
desired therapeutic approach is that that can 
control appetite or increase energy expenditure 
avoiding the chronic positive energetic balance 
[66]. On another hand, change or transplant of 
microbiota may be a chance to revert changes 
in gut microflora in obese patients [67]. 
However, this option has been recently 
questioned after the US Food and Drug 
Administration informed the death of one 
patient by contamination with Clostridium 
difficile during a clinical trial. Consequently, 
more research is needed on this target.  
 
Adipose tissue inflammation is a consequence 
of a metabolic inflammation process [10]. 
Macrophage activation by either FFAs or 
endotoxin should be targeted. The common link 
between these two stressors is the NF-kB 
signaling pathway [14], Table 1. Indeed, 
endotoxin and FFA (palmitic-, miristic- and 
stearic- fatty acids) activate innate immune 
cells by binding to TLR-4 and TLR-2, 
respectively, thus contribute to metabolic 
inflammation in the adipose tissue. Activation 
of TLRs in macrophages leads to signal 
transduction that induces NF-B activation-the 
master regulator of the inflammatory response 
[14]. Tissue cell activation with production of 
chemokines may be anther target, because these 
attract monocytes that differentiate into M1 
macrophages. MCP-1 and 4-1BB are 
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interesting target and the use of 
peptidomimetics should be further explored to 
interfere in the binding to its receptors in 
monocytes [10.68,69] The microenvironment 
of metabolically irritated adipose tissue by 
FFAs may be another target. In the irritated and 
hypoxic environment of metabolically stressed 
adipose tissue, recruited monocytes 
differentiate into M1-inflammatory 
macrophages [12], which produce large 
quantities of pro-inflammatory cytokines and 
reactive biochemical species (reactive oxygen 
species, nitrogen reactive species, and 
macromolecule end-oxidation products) [10]. 
Thus, the first level of intervention should be 




Previously has been shown that Nrf2 is an 
important transcription factor controlling the 
expression of two transcription factors master 
regulators of adipogénesis [70]. These 
transcription factors are PPAR- and CEBP- 
[72]. These transcription factors control the 
expression of adipogenic enzymes that catalyze 
the synthesis of tryglicerides—the safest way to 
store excess FFAs [73]. Thus, by activating 
Nrf-2 circulating concentrations of FFAs can be 
reduced and systemic inflammation reduced as 
well as metabolic complications of obesity, 
such as pulmonary inflammation [71]. In this 
regard we have found that the nitrone spin trap 
DMPO can block alternative activation of 
macrophages by the endotoxin 
lipopolysaccharide [74-76]. This spin trap also 
causes transcriptomic changes related to an 
inhibition of the expression of genes related to 
inflammatory activation [74]. The inhibitory 
effect of DMPO on LPS-induced macrophage 
activation was due to the direct binding of the 
spin trap to four specific residues in the TIR 
domain of TLRs (TLR2) named BB-loop [75].  
 
Myeloperoxidase and HOCl may be another 
target for preventing pulmonary neutrophilic 
inflammation in obesity (Table 1). Indeed, 
neutrophils, MPO and markers of HOCl-
promoted oxidations have been observed in the 
lung of obese patients and in mouse models of 
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diet-induced obesity and metabolic syndrome. 
Thus, the development of inhibitors of MPO or 
scavengers of HOCl may prove to be effective 
in preventing adipose tissue dysfunction 
(adipokine dysbalance, insulin resistance and 
cell death). Targeting the lung by using MPO 
inhibitors or HOCl scavengers may prove to be 
effective to prevent the contribution of 
pulmonary neutrophilic inflammation towards 
systemic inflammation, the leading cause of 
obesity-associated metabolic abnormalities 
(Figure 2). Thus, targeting inflammation and 
oxidative stress in the growing adipose tissue 
and lung is an attractive strategy to prevent 
obesity-associated co-morbidities and probably 
obesity associated cancers.  
 
Concluding Remarks  
 
Obesity is state of chronic low-grade 
inflammation caused by a chronic positive 
energy balance. This causes adipose tissue 
inflammation with infiltration of monocytes 
that acquire an inflammatory phenotype. The 
adipose tissue is inflamed and oxidants 
overwhelm the antioxidant capacity causing 
oxidative stress. Oxidized products as well as 
pro-inflammatory cytokines are secreted into 
the systemic circulation where it can activate 
neutrophils as well as activate NF-B, and other 
inflammatory transcription factors leading to 
expression of neutrophil adhesion molecules in 
the lung microvasculature. Oxidative stress and 
inflammation in the lung increased the systemic 
pool of pro-inflammatory and end-oxidation 
products that reduce insulin sensitivity and 
cause other metabolic abnormalities-associated 
to obesity. Therapeutic strategies to reduce the 
pulmonary contribution towards systemic 
inflammation are needed. These should be 
focused in reducing neutrophilic inflammation 
in the lung microvasculature (see Table 1). 
They include improving fatty acid storage in 
adipose tissue by inducing Nrf-2, reducing 
inflammatory activation of adipose tissue 
macrophages, inhibiting MPO activity and 
scavenging HOCl in the lung. These 
approaches are active fields of research in our 
laboratories.  
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